Treatments with PARPi in ovarian cancer cells in vitro and in vivo resulted in enrichment of CD133+ and CD117+ CSC, suggesting a need for a combination regimen with CSC-targeted therapies[71]. This evidence concerns the gene PROM1 and ovarian cancer.